908 W. Walnut Street Indianapolis
IN 46202
In July of 2019, the IBRI announced the appointment of world-renowned diabetes researcher, Decio Eizirik, M.D.,PhD as a senior research fellow. His international reputation as an innovator and his ability to create connections with researchers world-wide to advance our understanding of diabetes and its manifestations, is an exciting new addition to the Lilly Diabetes Center of Excellence in the IBRI Diabetes Center. At this Scientific Frameworx event, Dr. Eizirik will share his novel research approaches to prevent the progressive loss of beta cell mass in diabetes and introduce to Indianapolis the new team of diabetes researchers who are working with him to build core laboratory capabilities in the Indiana life sciences eco-system.
Decio L. Eizirik
Decio L. Eizirik, M.D., Ph.D., is Professor at the ULB Center for Diabetes Research, Medical Faculty, Universite Libre de Bruxells (ULB) Belgium and Research Fellow, IBRI, Indianapolis. He has published >350 full papers and reviews in peer-reviewed international journals and he has received several national and international prizes including the Juvenile Diabetes Research Foundation (JDRF) Diabetes Care Research Award, 1998, the “2012 Albert Renold Prize Lecture for Outstanding Achievements in Research on the Islets of Langernhans” awarded by the European Association for the Study of Diabetes (EASD), Berlin, Germany, 2012 and the “2013 Rumbough Award for outstanding achievements in type 1 diabetes research,” awarded by the JDRF, New York, 2013. He is listed by the ISI Essential Science Indicators among the 1% most cited scientists in Clinical Medicine and Biology & Biochemistry, with an h-index of 79. Dr. Eizirik has served as Honorary (Scientific) Secretary of the EASD and as Deputy Editor of Diabetologia. His research focuses on the molecular mechanisms regulating insulitis and beta cell apoptosis in type 1 diabetes and on the search for novel approaches to prevent the progressive loss of beta cell mass in diabetes.
Dr. Eizirik will be joined by:
Donalyn Scheuner, Ph.D., started with the IBRI in March 2019 as senior staff scientist in the IDC. She is responsible for planning and coordinating the research on the mechanisms of pancreatic beta cell dysfunction and death in TD1, working in close collaboration with Dr. Eizirik. She was previously a scientific consultant and a senior scientist with Eli Lilly and Company (Lilly).
Jonathan Flak, Ph.D., joined the IBRI on Sept. 1, 2019, as senior scientist. He will further develop a program studying the central nervous system’s regulation of glucose metabolism as it relates to diabetes. He was previously a research investigator in the University of Michigan Medical School’s Department of Internal Medicine in Ann Arbor, Mich.
Robert Considine, Ph.D., joined the Division of Endocrinology at the Indiana University School of Medicine in Indianapolis, Ind., as an Assistant Professor in 1997 and was promoted to Professor in 2013. Prior to his appointment at the IU School of Medicine, he was on the faculty of the Department of Medicine at Thomas Jefferson University in Philadelphia, Pa., where he had completed his doctoral training.
